NCT04176588

A Phase 3 Study of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis

A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Etrasimod for Induction and Maintenance Treatment in Subjects With Moderately to Severely Active Ulcerative Colitis

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 341 (actual)
• Sponsor: Everstar Therapeutics Limited · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether etrasimod is a safe and effective treatment for moderately to severely active ulcerative colitis. Condition or disease: Ulcerative Colitis Intervention/treatment: Drug: Etrasimod Drug: Placebo Phase: Phase 3

Conditions

• Moderately to Severely Active Ulcerative Colitis

Interventions

Type	Name	Description
DRUG	Etrasimod	Drug:Etrasimod Tablet other name:APD334
DRUG	Placebo	Drug:placebo Tablet

Timeline

• Start date: 2019-09-10
• Primary completion: 2024-07-01
• Completion: 2024-10-01
• First posted: 2019-11-25
• Last updated: 2024-01-09

Locations

1 site across 1 country: China